慢加急性肝衰竭的免疫治疗

覃小宾; 张荣臻; 吴聪; 曾胜澜; 乐滢玉; 毛德文

doi:10.3969/j.issn.1001-5256.2021.11.046

慢加急性肝衰竭的免疫治疗

DOI: 10.3969/j.issn.1001-5256.2021.11.046

1.
广西中医药大学研究生学院，南宁 530001
2.
广西中医药大学第一附属医院肝病科，南宁 530023

基金项目:

国家自然科学基金 (81960841);

国家自然科学基金面上项目 (82060848);

广西自然科学基金课题 (2018GXNSFAA281096);

广西自然科学基金课题 (2020JJA140273)

详细信息

通信作者:
毛德文，mdwboshi2005@163.com

中图分类号: R575.3
计量
- 文章访问数: 567
- HTML全文浏览量: 166
- PDF下载量: 63
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-28
- 录用日期: 2021-04-21
- 出版日期: 2021-11-20

Immunotherapy for acute-on-chronic liver failure

1.
Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, China
2.
Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

National Natural Science Foundation Project (81960841);

General Project of National Natural Science Foundation Project (82060848);

Guangxi Natural Science Fund Project (2018GXNSFAA281096);

Guangxi Natural Science Fund Project (2020JJA140273)

摘要

摘要: 慢加急性肝衰竭(ACLF)是一种严重威胁生命的疾病，具有多器官衰竭、脓毒症和死亡的高风险。ACLF在体内激活先天免疫反应和获得性免疫反应，从而引起持续的全身炎症反应综合征和多器官功能障碍的发展，导致该病的高病死率。失调的免疫反应在疾病进展中起关键作用，免疫疗法可能有助于针对免疫介导的器官损伤，抑制肝衰竭的进展，就目前ACLF中具有潜在免疫调节作用的药物与手段的作用及其机制进行了综述，以期为ACLF的免疫治疗提供参考。
- 慢加急性肝功能衰竭 /
- 免疫调节 /
- 肝再生 /
- 药用制剂 /
- 肝, 人工
Abstract: Acute-on-chronic liver failure (ACLF) is a life-threatening disease with a high risk of multiple organ failure, sepsis, and death. ACLF activates innate and acquired immune responses in human body and thus leads to the progression of persistent systemic inflammatory response syndrome and multiple organ dysfunction, leading to the high mortality rate of this disease. Dysregulated immune response plays a key role in disease progression, and immunotherapy may help to target immune-mediated organ damage and inhibit the progression of liver failure. This article reviews the role and mechanism of drugs and means with a potential immune regulatory effect in ACLF, in order to provide a reference for immunotherapy for ACLF.
- Acute-On-Chronic Liver Failure /
- Immunomodulation /
- Liver Regeneration /
- Pharmaceutical Preparations /
- Liver, Artificial

HTML全文

参考文献(49)

[1]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[2]	YIN S, WANG SJ, GU WY, et al. Risk of different precipitating events for progressing to acute-on-chronic liver failure in HBV-related cirrhotic patients[J]. J Dig Dis, 2017, 18(5): 292-301. DOI: 10.1111/1751-2980.12480.
[3]	SATSANGI S, DUSEJA A, SACHDEVA M, et al. Monocyte human leukocyte antigen - Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure[J]. PLoS One, 2018, 13(7): e0200644. DOI: 10.1371/journal.pone.0200644.
[4]	CHEN P, WANG YY, CHEN C, et al. The immunological roles in acute-on-chronic liver failure: An update[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(5): 403-411. DOI: 10.1016/j.hbpd.2019.07.003.
[5]	SHUBHAM S, KUMAR D, ROOGE S, et al. Cellular and functional loss of liver endothelial cells correlates with poor hepatocyte regeneration in acute-on-chronic liver failure[J]. Hepatol Int, 2019, 13(6): 777-787. DOI: 10.1007/s12072-019-09983-y.
[6]	MA HC, SHI XL, REN HZ, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liver regeneration[J]. World J Gastroenterol, 2014, 20(40): 14884-14894. DOI: 10.3748/wjg.v20.i40.14884.
[7]	LEI Y, LIU Z, HAN Q, et al. G-CSF enhanced SDF-1 gradient between bone marrow and liver associated with mobilization of peripheral blood CD34⁺ cells in rats with acute liver failure[J]. Dig Dis Sci, 2010, 55(2): 285-291. DOI: 10.1007/s10620-009-0757-9.
[8]	KHANAM A, TREHANPATI N, GARG V, et al. Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure[J]. Liver Int, 2014, 34(4): 505-513. DOI: 10.1111/liv.12415.
[9]	SHARMA S, LAL SB, SACHDEVA M, et al. Role of granulocyte colony stimulating factor on the short-term outcome of children with acute on chronic liver failure[J]. J Clin Exp Hepatol, 2020, 10(3): 201-210. DOI: 10.1016/j.jceh.2019.10.001.
[10]	KARIMINEKOO S, MOVASSAGHPOUR A, RAHIMZADEH A, et al. Implications of mesenchymal stem cells in regenerative medicine[J]. Artif Cells Nanomed Biotechnol, 2016, 44(3): 749-757. DOI: 10.3109/21691401.2015.1129620.
[11]	LIN BL, CHEN JF, QIU WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial[J]. Hepatology, 2017, 66(1): 209-219. DOI: 10.1002/hep.29189.
[12]	MOUNAYAR M, KEFALOYIANNI E, SMITH B, et al. PI3kα and STAT1 interplay regulates human mesenchymal stem cell immune polarization[J]. Stem Cells, 2015, 33(6): 1892-1901. DOI: 10.1002/stem.1986.
[13]	JITSCHIN R, BÖTTCHER M, SAUL D, et al. Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation[J]. Leukemia, 2019, 33(7): 1783-1796. DOI: 10.1038/s41375-018-0376-6.
[14]	LIEDER R, SIGURJONSSON OE. The effect of recombinant human interleukin-6 on osteogenic differentiation and YKL-40 expression in human, bone marrow-derived mesenchymal stem cells[J]. Biores Open Access, 2014, 3(1): 29-34. DOI: 10.1089/biores.2013.0035.
[15]	LIU Q, CHEN X, LIU C, et al. Mesenchymal stem cells alleviate experimental immune-mediated liver injury via chitinase 3-like protein 1-mediated T cell suppression[J]. Cell Death Dis, 2021, 12(3): 240. DOI: 10.1038/s41419-021-03524-y.
[16]	NEONG SF, ADEBAYO D, WONG F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 293-305. DOI: 10.1080/17474124.2018.1555469.
[17]	ARNAU-BARRÉS I, GVERRI-FERNÁNDEZ R, LUQUE S, et al. Serum albumin is a strong predictor of sepsis outcome in elderly patients[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(4): 743-746. DOI: 10.1007/s10096-019-03478-2.
[18]	O'Brien AJ, BRIEN AJ, FULLERTON JN, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2[J]. Nat Med, 2014, 20(5): 518-523. DOI: 10.1038/nm.3516.
[19]	CARACENI P, PAVESI M, BALDASSARRE M, et al. The use of human albumin in patients with cirrhosis: A European survey[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(6): 625-632. DOI: 10.1080/17474124.2018.1460203.
[20]	GIANNONE FA, DOMENICALI M, BALDASSARRE M, et al. Ischaemia-modified albumin: A marker of bacterial infection in hospitalized patients with cirrhosis[J]. Liver Int, 2015, 35(11): 2425-2432. DOI: 10.1111/liv.12860.
[21]	KUMAR PA, SUBRAMANIAN K. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease[J]. J Clin Diagn Res, 2016, 10(3): BC09-12. DOI: 10.7860/JCDR/2016/17168.7399.
[22]	GAO L, WANG JF, XIANG M, et al. Expression of human glucocorticoid receptor in T lymphocytes in acute-on-chronic hepatitis B liver failure[J]. Dig Dis Sci, 2011, 56(9): 2605-2612. DOI: 10.1007/s10620-011-1656-4.
[23]	SHIMBA A, CUI G, TANI-ICHI S, et al. Glucocorticoids drive diurnal oscillations in T cell distribution and responses by inducing interleukin-7 receptor and CXCR4[J]. Immunity, 2018, 48(2): 286-298. e6. DOI: 10.1016/j.immuni.2018.01.004.
[24]	YU X, LAN P, HOU X, et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production[J]. J Hepatol, 2017, 66(4): 693-702. DOI: 10.1016/j.jhep.2016.12.018.
[25]	ZHAO Q, WU CS, FANG Y, et al. Glucocorticoid regulates NLRP3 in acute-on-chronic hepatitis B liver failure[J]. Int J Med Sci, 2019, 16(3): 461-469. DOI: 10.7150/ijms.30424.
[26]	ZHE-BIN W, KE W, MO ZS, et al. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure[J]. Clin Res Hepatol Gastroenterol, 2020 : 101505. DOI: 10.1016/j.clinre.2020.07.010.[Onlineaheadofprint]
[27]	HUANG C, YU KK, ZHENG JM, et al. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: A 10-year cohort study in a university hospital in East China[J]. J Dig Dis, 2019, 20(1): 38-44. DOI: 10.1111/1751-2980.12691.
[28]	THURSZ MR, RICHARDSON P, ALLISON M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis[J]. N Engl J Med, 2015, 372(17): 1619-1628. DOI: 10.1056/NEJMoa1412278.
[29]	TAUBERT R, HARDTKE-WOLENSKI M, NOYAN F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies[J]. J Hepatol, 2014, 61(5): 1106-1114. DOI: 10.1016/j.jhep.2014.05.034.
[30]	OO YH, WESTON CJ, LALOR PF, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver[J]. J Immunol, 2010, 184(6): 2886-2898. DOI: 10.4049/jimmunol.0901216.
[31]	FU XQ, CAI JY, LI MJ. Prednisone may rebuild the immunologic homeostasis: Alteration of Th17 and Treg cells in the lymphocytes from rats' spleens after treated with prednisone-containing serum[J]. Mol Genet Genomic Med, 2019, 7(7): e00800. DOI: 10.1002/mgg3.800.
[32]	KARKHANIS J, VERNA EC, CHANG MS, et al. Steroid use in acute liver failure[J]. Hepatology, 2014, 59(2): 612-621. DOI: 10.1002/hep.26678.
[33]	CHI JH, SEO GS, LEE SH. Oregonin inhibits inflammation and protects against barrier disruption in intestinal epithelial cells[J]. Int Immunopharmacol, 2018, 59: 134-140. DOI: 10.1016/j.intimp.2018.04.006.
[34]	SHAO C, TIAN G, HUANG Y, et al. Thymosin alpha-1-transformed bifidobacterium promotes T cell proliferation and maturation in mice by oral administration[J]. Int Immunopharmacol, 2013, 15(3): 646-653. DOI: 10.1016/j.intimp.2012.12.031.
[35]	SUGAHARA S, ICHIDA T, YAMAGIWA S, et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B[J]. Hepatol Res, 2002, 24(4): 346-354. DOI: 10.1016/s1386-6346(02)00145-6.
[36]	BOZZA S, GAZIANO R, BONIFAZI P, et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo[J]. Int Immunol, 2007, 19(11): 1261-1270. DOI: 10.1093/intimm/dxm097.
[37]	YAO Q, DOAN LX, ZHANG R, et al. Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14⁺ monocytes[J]. Immunol Lett, 2007, 110(2): 110-120. DOI: 10.1016/j.imlet.2007.04.007.
[38]	GARACI E, PICA F, SERAFINO A, et al. Thymosin α1 and cancer: Action on immune effector and tumor target cells[J]. Ann N Y Acad Sci, 2012, 1269: 26-33. DOI: 10.1111/j.1749-6632.2012.06697.x.
[39]	NAYLOR PH, MUTCHNICK MG. Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach[J]. J Viral Hepat, 2018, 25(1): 4-9. DOI: 10.1111/jvh.12807.
[40]	PENG D, XING HY, LI C, et al. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2020, 20(1): 348. DOI: 10.1186/s12876-020-01477-8.
[41]	WU J, ZHOU L, LIU J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): A multicenter, single-blind, randomized and controlled trial[J]. Crit Care, 2013, 17(1): R8. DOI: 10.1186/cc11932.
[42]	SARIN SK, CHOUDHURY A. Acute-on-chronic liver failure: terminology, mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(3): 131-149. DOI: 10.1038/nrgastro.2015.219.
[43]	YANG L, WU T, LI J, et al. Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: A case-control matched analysis[J]. Hepatol Res, 2020, 50(6): 656-670. DOI: 10.1111/hepr.13497.
[44]	LARSEN FS, SCHMIDT LE, BERNSMEIER C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64(1): 69-78. DOI: 10.1016/j.jhep.2015.08.018.
[45]	OCSKAY K, KANJO A, GEDE N, et al. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: A systematic review and network meta-analysis[J]. Ann Intensive Care, 2021, 11(1): 10. DOI: 10.1186/s13613-020-00795-0.
[46]	KHAMRI W, ABELES RD, HOU TZ, et al. Increased expression of cytotoxic T-lymphocyte-associated protein 4 by T cells, induced by B7 in sera, reduces adaptive immunity in patients with acute liver failure[J]. Gastroenterology, 2017, 153(1): 263-276. e8. DOI: 10.1053/j.gastro.2017.03.023.
[47]	ZHANG Z, ZHAO YC, CHENG Y, et al. Hybrid bioartificial liver support in cynomolgus monkeys with D-galactosamine-induced acute liver failure[J]. World J Gastroenterol, 2014, 20(46): 17399-17406. DOI: 10.3748/wjg.v20.i46.17399.
[48]	BAÑARES R, NEVENS F, LARSEN FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial[J]. Hepatology, 2013, 57(3): 1153-1162. DOI: 10.1002/hep.26185.
[49]	KRIBBEN A, GERKEN G, HAAG S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure[J]. Gastroenterology, 2012, 142(4): 782-789. e3. DOI: 10.1053/j.gastro.2011.12.056.